Original article| Volume 10, ISSUE 3, P150-154, December 1999

Download started.


Postprandial serum cholylglycine in the detection of hepatotoxicity induced by antituberculous agents


      Background: Measurement of bile acid levels has been proven helpful in the detection of hepatic abnormalities when routine liver function test results are normal or only slightly elevated. We compared the effectiveness of postprandial serum cholylglycine (CG), as determined by RIA, with commonly used liver function tests (SGOT, SGPT, alkaline phosphatase, gamma-glutamyl transpeptidase) in order to detect liver injury in patients receiving antituberculous agents. Method: We studied 100 patients receiving antituberculous agents. Laboratory tests were carried out before the initiation of therapy and after 1, 2, 3 and 8 weeks of treatment. The risk of hepatotoxicity in relation to age (>35 years) and/or the addition of pyrazinamide to the 6-month isoniazid–rifampin regimen was also assessed. Results: The percentage of patients with hepatic dysfunction detected by abnormal serum CG levels was significantly greater than that detected with conventional liver function tests. Neither age over 35 years nor the use of pyrazinamide was associated with a greater number of abnormalities in liver function tests. Conclusion: Postprandial serum CG by RIA proved to be a sensitive parameter for detecting hepatotoxicity by antituberculous agents.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hofmann AF
        • Molino G
        • Milanese M
        • Belforte G
        Description and simulation of a physiological pharmacokinetic model for the metabolism and enterohepatic circulation bile acids in man.
        J Clin Invest. 1983; 71: 1003-1022
        • Paré P
        • Hoefs JC
        • Ashcaval M
        Determinants of serum bile acids in chronic liver disease.
        Gastroenterology. 1991; 81: 959-964
        • Sherlock S
        • Walshe V
        Blood cholates in normal subjects and in liver disease.
        Clin Sci. 1948; 6: 959-964
        • Festi D
        • Morselli Labate AM
        • Roda A
        • Bazzoli F
        • Frabboni R
        • Rucci P
        • et al.
        Diagnostic effectiveness of serum bile acids in liver disease as evaluated by multivariate statistical methods.
        Hepatology. 1983; 3: 707-713
        • Ferraris R
        • Colombatti G
        • Fiorentini MT
        • Carosso R
        • Arossa W
        • De La Pierre M
        Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary disease. Sensitivity, specificity, and predictive value.
        Dig Dis Sci. 1983; 28: 129-136
        • Barnes PF
        • Bloch AB
        • Davidson PT
        • Snider Jr, DE
        Tuberculosis in patients with human immunodeficiency virus infection.
        N Engl J Med. 1991; 324: 1644-1650
        • Van Scoy RE
        • Wilkowske CJ
        Antituberculous agents.
        Mayo Clin Proc. 1987; 62: 1129-1136
        • Gangadharam PRJ
        Isoniazid, rifampin, and hepatotoxicity.
        Am Rev Respir Dis. 1986; 133: 963-965
        • Combs DL
        • O'Brien RJ
        • Geiter LJ
        USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results.
        Ann Intern Med. 1990; 112: 397-406
        • Pretet S
        • Perdrizet S
        Le toxicité du pyrazinamide dans le traitements antituberculeux.
        Rev Fr Mal Respir. 1980; 8: 307-320
        • Rapp RS
        • Campbell RW
        • Howell JC
        • Kendig Jr, EL
        Isoniazid hepatotoxicity in children.
        Am Rev Respir Dis. 1978; 118: 794-796
        • Kaplowitz N
        • Kok E
        • Javitt NB
        Postprandial serum bile acid for the detection of hepatobiliary disease.
        JAMA. 1973; 225: 292-293
        • Roda A
        • Roda E
        • Aldini R
        • Capelli M
        • Festi D
        • Sama C
        • et al.
        Results of six `kit' radioimmunoassays for primary bile acids in human serum intercompared.
        Clin Chem. 1980; 26: 1677-1682
      1. SPSS for windows. Release 6.0. Chicago (IL): SPSS, 1993.

        • Iwamura K
        Changes of plasma bile acid levels and their clinical significance in drug-induced liver injury.
        Tokai J Exp Clin Med. 1984; 9: 109-117
        • Black M
        • Mitchell JR
        • Zimmerman HJ
        • et al.
        Isoniazid-associated hepatitis in 114 patients.
        Gastroenterology. 1975; 69: 289-302
        • Mitchell JR
        • Zimmerman HJ
        • Ishak KG
        • Thorgeirsson UP
        • Timbrell JA
        • Snodgrass WR
        • et al.
        Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
        Ann Intern Med. 1976; 84: 181-192
        • Mitchell I
        • Wendon J
        • Fitt S
        • Williams R
        Anti-tuberculous therapy and acute liver failure.
        Lancet. 1995; 345: 555-556
        • Steele MA
        • Burk RF
        • Desprez RM
        Toxic hepatitis with isoniazid and rifampin. A meta-anaylisis.
        Chest. 1991; 99: 465-471
        • Snider DE
        • Caras GJ
        Isoniacid-associated hepatitis deaths: a review to available information.
        Am Rev Respir Dis. 1992; 145: 494-497
        • Lees AW
        • Asgher B
        • Hashem MA
        • Sinha BN
        Juandice after rifampicin.
        Br J Dis Chest. 1970; 64: 90-95
        • Furet Y
        • Metman EH
        • Bertrand J
        • Breteau M
        Hepatite mixte a la rifamycine SV. A propos d'un cas.
        Therapie. 1986; 41: 421-423
        • Scheuer PJ
        • Summerfield JA
        • Lal S
        • Sherlock S
        Rifampicin hepatitis. A clinical and histological study.
        Lancet. 1974; ii: 421-423
        • American Thoracic Society
        Treatment of tuberculosis and tuberculosis infection in adults and children.
        Am J Respir Crit Care Med. 1994; 146: 1622-1633
        • Duran F
        • Jebrak G
        • Pessayre D
        • Fournier M
        • Bernau J
        Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
        Drug Staf. 1996; 15: 394-405
        • Osmerold LP
        • Skinner C
        • Wales J
        Hepatotoxicity of antituberculous drugs.
        Thorax. 1996; 51: 111-113
        • Lauterburg BH
        • Smith CV
        • Todd EL
        • Mitchell JR
        Pharmacokinetics of the toxic hydrazinometabolites formed from isoniazid in humans.
        J Pharmacol Exp Ther. 1985; 235: 566-570
        • Schaberg T
        • Rebhan K
        • Lode H
        Risk factors for side-effects of isoniacid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
        Eur Respir J. 1996; 9: 2026-2030
        • Van Aalderen WMC
        • Knoester H
        • Knol K
        Fulminant hepatitis during treatment with rifampicin, pyrazinamide and ethambutol.
        Eur J Pediatr. 1987; 146: 290-291
        • Parthasarathy R
        • Raghupati Sarma G
        • Janardhanam B
        • Ramachandran P
        • Santha T
        • Sivasubramanian S
        • et al.
        Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampin and pyrazinamide.
        Tubercle. 1986; 67: 99-108
        • Vidal Pla R
        • de Gracia X
        • Gallego B
        • Algueró C
        • Bravo C
        Hepatotoxicidad del tratamiento de la tuberculosis.
        Med Clin (Barcelona). 1991; 97: 481-485
        • Hong Kong Chest Service/British Medical Research Council
        Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis.
        Lancet. 1981; i: 171-174